Background: Resistance to thyroid hormone (RTH) is a syndrome characterized by refractoriness of the pituitary and/or peripheral tissues to the action of thyroid hormone. Mutations in the thyroid hormone receptor ,B
INTRODUCTION
Thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily, which includes the vitamin D receptor, retinoic acid re-ceptor, retinoid X receptor (RXR) and steroid receptors. They act as nuclear transcription factors that bind to specific thyroid hormone response elements (TREs) on the promoters of 3,5,3' -triiodo-L-thyronine (T3) -responsive genes (1, 2) . Two TR genes, a and 1B, located on chromosome 17 and 3, respectively, have been identified. Alternative splicing of the primary transcripts of these two genes yields three isoforms of TR, al, , 31 , and ,B2, each with a unique develop-304 Molecular Medicine, Volume 3, Number 5, May 1997 mental and tissue-specific expression (1, 2) . The transcriptional activity of TRs is not only regulated by T3 and the types of TREs, but also by other cellular proteins, including the tumor suppressor p53 (3) , corepressors (4), coactivators (4) , and other members of the nuclear receptor superfamily (1) .
Resistance to thyroid hormone (RTH) is a genetic disease due to mutations in the TRf3 gene (5, 6) . This clinical syndrome was first described by Refetoff et al. (7) and is characterized by an inappropriately normal or elevated level of thyroid-stimulating hormone (TSH) for the elevated levels of circulating thyroid hormones. Clinical features include attention-deficit hyperactivity disorder (ADHD), decreased IQ, dyslexia, short stature, decreased weight, tachycardia, and cardiac disease (5, 6, 8) . TR,B mutants derived from RTH patients have reduced T3-binding affinities and transcriptional capacities and, unlike other nuclear receptor mutations causing hormone-resistance syndromes, act in a dominant negative fashion to cause the clinical phenotype (5, 6, 9) . Until recently, all the studies of mutant TR,B action were performed in in vitro systems and in cell culture. The findings from these systems have well-recognized limitations when extrapolated to the physiological context. In one approach, Hayashi et al. (10) used an adenovirus to target mouse liver with a mutant TRf31 to study the dominant negative action of the mutant receptor on this tissue. In terms of a whole animal model of RTH, it was initially postulated that the overexpression of v-erbA might produce a phenotype analogous to that seen in RTH (11) . VerbA, which is the viral counterpart of the c-erbA gene that encodes the chicken TRa (12, 13) , is also a dominant negative transcription factor, but unlike TR, it is a potent oncogene. Transgenic (TG) mice overexpressing v-erbA under the control of the human f3-actin promoter ( 11) had low thyroid hormone levels in the presence of inappropriately low TSH responses to Methimazole and thyroid follicle abnormalities, reduced fertility, decreases in body mass, abnormal mothering behavior, and hepatocellular carcinoma. Thus, these features were markedly different from those observed in RTH despite the close relationship between these two transcription factors. In a more recent study of TR, knockout mice, Forrest et al. (14) found that these mice closely resembled the only kindred described with a recessive form of RTH (7) where the TRf3 gene was deleted (15) in that these mice had goiter, high L-thyroxine (T4) and T3 values with inappropriately normal TSH levels, and deafness. However, unexpectedly and in marked contrast to the frequent presentation of behavioral abnormalities in kindreds with RTH, these mice lacked any overt behavioral abnormalities. Thus, the mechanisms that mediate mutant TR,B action in the brain in dominantly inherited RTH are distinct to those in recessive RTH. Indeed, in this study in which we report the development of TG mice overexpressing a powerful dominant negative human mutant TR31, PV, under the control of the human 03-actin promoter (16, 17) , we observed behavioral abnormalities. PV was derived from a patient with severe RTH characterized by ADHD, short stature (<5 percentile), low weight (<5 percentile), goiter, and tachycardia (18) . PV has a unique mutation in exon 10, a C-insertion at codon 448, which produces a frameshift of the carboxy terminal 16 amino acids of TR,31, resulting in total loss of T3-binding and transcriptional activation (19) . Thus, in contrast to v-erbA TG mice (11) , TG mice harboring PV exhibited elevated thyroid hormone levels with inappropriately normal TSH levels, impaired weight gain, and hyperactivity, features which are similar to those seen in RTH. Moreover, PV TG mice differed from TRf3 knockout mice in having a behavioral phenotype, which underscores the importance of these different animal models in the further understanding of the molecular basis of thyroid hormone action.
MATERIALS AND METHODS Plasmids
Mutant PV TR,31 cDNA constructed as previously described (19) After purification of the PCR products using the SpinBind PCR purification system (FMC Bioproducts, Rockland, ME), restriction digestion with PstI was carried out and the different fragments separated on an 8% polyacrylamide gel. Ratios of PV:mTR,3l mRNA were obtained using PhosphoImager analysis of the dried gel after overnight exposure (Molecular Dynamics, Sunnyvale, CA).
Preparation of Specific PV Antibody and Detection of PV Protein in Liver by Immunohistochemistry Polyclonal anti-PV antibody TI was prepared and affinity purified as described (21) . TI Fig. IB) .
To detect the expression of PV protein, we developed a rabbit polyclonal antibody, TI, specifically against the unique frame-shifted C-terminal 16 amino acids of the mutant PV (21). TI does not recognize the wild-type TRI31 (21) . We used immunohistochemistry to detect the expression of PV protein in liver. For control, the endogenous wild-type mTRI3l was detected in the nuclei of liver cells of both NTG and TG mice ( Fig. 2C and D, respectively) by using mouse monoclonal antibody C4 (21) . While this method required the use of anti-mouse IgG labeling, the pattern of endogenous IgG seen in the hepatic sinusoids (arrowheads in Fig. 2A and B, controls) did not interfere with the ability to detect hepatocyte nuclear TR. Immunohistochemistry using a rabbit polyclonal antibody Ti demonstrated the presence of specific PV protein within the nuclei of liver cells of a TG mouse from Family D (Fig. 2F ) and no reactivity with hepatocyte nuclei from a normal mouse (Fig. 2E ). Since this method used an anti-rabbit IgG second antibody rather than anti-mouse IgG, no background IgG was found in sinusoids ( Fig. 2E and F) . Figure 2A and B show the blank controls omitting the use of the primary antibodies.
We have also examined the expression of PV protein in the brain. Unlike the liver, the distribution in the brain of cell nuclei reactive with the T1 antibody in a TG mouse from Family D was confined to specific areas. Although it was not possible to make a precise anatomical determination of the location of these cells, their distribution was consistent with a subset of temporal cortical neurons (Fig. 3) . Comparable areas of NTG mouse brain failed to show any specific nuclear reactivity (data not shown). Taken together, the expression of PV was not only detected at the RNA level but also at the protein level.
Elevated Thyroid Hormone Levels and Inappropriate TSH Response in Transgenic Mice
Thyroid function tests from TG founder mice showed significant elevations of both total T4 and free T4 levels (Fig. 4) . The mean (± SEM) total T4 value for TG mice was 3.63 ± 0.32 mg/dl and for NTG mice, 2.83 ± 0.13 mg/dl (p < 0.01). The free T4 value for TG mice was 2.14 ± 0.12 ng/dl and 1.85 ± 0.07 ng/dl for NTG mice (t-test, difference significant with p < 0.05). However, there were no differences in total T3 values between TG (1.14 ± 0.02 ng/ml) and NTG mice (1.15 ± 0.01 ng/ml). Serum TSH was inappropriately normal for TG mice, with a mean of 47.7 ± 3.71 ng/dl, which was not significantly (Fig. 5C ).
Transgenic Mice Exhibit Hyperact
The most common clinical feature of R ing treatment is ADHD, which affec children and 42% of adults with RTI disorder is characterized by motor re impulsivity, and distractibility. Althoiu is common in the general population associated with only a small proporti( cases; however, TRf3 mutations represent the only known genetic association with ADHD (25) .
To assess whether TG mice exhibit the phenotype of increased activity consistent with that observed in RTH kindreds, we measured their nocturnal stereotypic activities (e.g., grooming, head bobbing, and licking). As shown in Fig. 6A , the activities of TG mice were increased by nearly isgenic 2-fold, indicating that TG mice were more active transgenic than NTG mice.
However, there were no significant differences in the daytime activity levels between TG and NTG mice. These results could reflect the fact that mice are nocturnal animals and hence differences in activity could be expected to be accentuated at night. To demonstrate the increased daytime activity in TG mice, we took advantage of an observation seen in the treatment of ADHD in RTH kindreds. Current treatment modalities for ADHD patients are not optimal and consist mostly of methylphenidate, a dopamine reuptake blocker with a mechanism of action similar to that of amphetamine (26) Despite the significantly higher level of T4 in TG mice as compared to NTG mice, no differences in the T3 levels were seen between the two groups. This puzzling observation suggests that the level of expression of mutant PV is probably not the only factor that determines the phenotype. The "expected" responses could be modified by downstream regulation events. One of the possibilities is that the activation of type I deiodinase enzyme activity, which is responsible for the conversion of T4 to T3, is inhibited in a dominant negative fashion by mutant PV, thus blocking the production of T3. Another way in which this TG mouse model has been useful is in the evaluation of behavioral findings which, while not necessarily mimicking human ADHD, would lend support to the association of ADHD to TRO3 gene mutations. Fur- thermore, the pattern of behavioral anomalies suggests the involvement of dopaminergic pathways. A central role of dopamine in hyperactivity has been demonstrated by several studies, including a report of dopamine DI receptor knockout mice which showed basal hyperactivity and elimination of cocaine-induced hyperactivity (29) , and a more recent study of a targeted mutation of the D3 dopamine receptor gene which resulted in hyperactivity (30) . Similarly, in an earlier rat model of hyperactivity, neonatal intracisternal administration of 6-hydroxydopamine, which resulted in severe depletion of dopamine in the striatum and nucleus accumbens, also caused marked basal hyperactivity that was reversed by low doses of amphetamine or methylphenidate (31) . Interestingly, it has been shown that dopamine may indirectly stimulate TRs to affect nuclear T3 responses via a ligand-independent fashion involving cross-talk with membrane-bound dopamine receptors and G-proteins (32) . Furthermore, there is evidence from rodent studies suggesting that hypothyroidism may upregulate dopamine receptors (33) . This may provide a possible explanation for the efficacy of dopamine reuptake blockers in improving the symptomatology of hyperactivity in RTH.
It is thus interesting to compare this model of dominant RTH with that of the recessive mouse model (14) . Whereas the latter identified functions of TR,B, such as for hearing and regulation of TSH in the pituitary, and TR,B cannot be substituted with TRa to carry these out, loss of TR,3 in this mouse model apparently had only relatively mild or undetectable consequences for brain development. Indeed, our study confirms the importance of mutant TRf3 function in disrupting certain neurological functions that result in the behavioral abnormalities observed in dominant RTH. The pathways that subserve the loss of receptor function and the presence of mutant receptor function may thus be different; our understanding of these mechanisms is enhanced by comparing different animal models.
